Estimating the potential impact of implementing pre?emptive pharmacogenetic testing in primary care across the UK

Aims Pharmacogenetics (PGx) in the UK is currently implemented secondary care for a small group of high-risk medicines. However, most prescribing takes place primary care, with large medicines influenced by commonly occurring genetic variations. The goal this study to quantitatively estimate volumes impacted implementation population-level, pre-emptive pharmacogenetic screening programme nine genes related frequently dispensed 2019. Methods A community pharmacy database was analysed national incidence first prescriptions 56 PGx drugs used period 1 January–31 December These estimated prescription were combined phenotype frequency data occurrence actionable drug–gene interactions (DGI) daily practice pharmacies. Results In between 19.1 and 21.1% (n = 5 233 353–5 780 595) all new 27 411 288 prescriptions/year), an interaction present according guidelines Dutch Working Group and/or Clinical Implementation Consortium. these cases, DGI would result either increased monitoring, guarding against maximum ceiling dose or optional immediate drug/dose change. An adjustment change drug regimen accounted 8.6–9.1% 2 354 058–2 500 283) prescriptions. Conclusions Actionable occur opportunity optimise prescribing.